Transposition of Great VesselsNCT05809310
Effects Branch PA Stenting d-TGA, ToF and TA
A study testing Percutaneous intervention (stent) for PA stenosis in people with Transposition of Great Vessels and Tetralogy of Fallot, run by UMC Utrecht at 4 sites in Netherlands.
Trial summary
The goal of this randomized controlled trial is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. Read more about this study
- Who is it for?
- Ages 8 years and older
- Conditions the study is for
- Transposition of Great Vessels, Tetralogy of Fallot, Truncus Arteriosus
- What is being tested?
- Percutaneous intervention (stent) for PA stenosis
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 56 participants
- Where
- 4 sitesNetherlands
- Study dates
- 18 Apr 2023to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Patients with d-TGA post ASO, ToF or TA
- ≥8 years
Who cannot join
- One or more of the following inclusion criteria:
- All class IIa indications for a branch PA intervention:
- Persistent decreased RV function (based on gold standard CMR)
- <18 years RVEF ≤55% (28)
- ≥18 years RVEF<50% (29)
- Progressive tricuspid regurgitation (TR) (≥moderate)
Show all 14Show fewer
- Isolated bifurcation stenosis:
- Significant unilateral stenosis (≥50%)
- Borderline bilateral PA stenosis (40-70%)
- Unbalanced perfusion (≤35/65%)
- RV/LV pressure ratio > 2/3 based on echocardiography
- Reduced lung perfusion or decreased objective exercise capacity (based of gold standard VO2 max during CPET)
- <18 years VO2 peak <35 mL∙kg-1∙min-1 (boys) VO2 peak <30 mL∙kg-1∙min-1 (girls) (30)
- ≥18 years VO2 peak <27 mL∙kg-1∙min-1 (men) VO2 peak <19 mL∙kg-1∙min-1 (women) (31)
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Renée Joosen, MSc contact
Netherlands4 sites, 4 recruiting
- Not yet recruiting
Amsterdam University Medical Center location AMC
Amsterdam, 1105 AZ
Nico A Blom, MD, PhD, N.A.Blom@amsterdamumc.nl
Renée S Joosen, MSc, r.s.joosen-2@umcutrecht.nl
- Not yet recruiting
Leiden University Medical Center
Leiden, 2333 ZA
Nico A Blom, MD, PhD, N.A.Blom@lumc.nl
Renée S Joosen, MSc, r.s.joosen-2@umcutrecht.nl
- Not yet recruiting
Erasmus Medical Center
Rotterdam, 3015 CN
Thomas B Krasemann, MD, PhD, t.krasemann@erasmusmc.nl
Renée S Joosen, MSc, r.s.joosen-2@umcutrecht.nl
- Recruiting
UMC Utrecht/WKZ
Utrecht, 3584 CX
Johannes MPJ Breur, MD, PhD, 0031887575459, h.breur@umcutrecht.nl
Renée S Joosen, MSc, r.s.joosen-2@umcutrecht.nl
About this study
Official title: The Effects of Branch Pulmonary Artery Stenting in d-TGA, ToF and TA: a Randomized Control Trial
The goal of this randomized controlled trial is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA.
The main question[s] it aims to answer are:
Read more
The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.
Participants will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.
Researchers will compare the difference in VO2 max (% predicted) between the interventional group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo a percutaneous intervention for a PA stenosis) and the control group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo conservative management)
Read the detailed description
Rationale: Postoperative survival of patients with dextro transposition of the great arteries (d-TGA), Tetralogy of Fallot (ToF) and Truncus Arteriosus (TA) has increased over the last decades due to advances in operative techniques and perioperative care. Despite postoperative survival has increased, morbidity of these patients increases during long-term follow-up with a high need for reinterventions. Right ventricular outflow tract (RVOT) obstructions are the most common indication for a reintervention and percutaneous branch pulmonary artery (PA) interventions account for a significant number of these reinterventions. However, the effects of percutaneous branch PA interventions on exercise capacity, RV function and RV adaptation of patients with d-TGA, ToF and TA remains largely unknown. In addition, there is no consensus about the optimal timing for percutaneous interventions for branch PA stenosis in international guidelines.
Objective: The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.
Study design: This is a multicenter randomized controlled trial. Patients will be included from the following Dutch interventional centers for congenital heart disease: UMC Utrecht/WKZ (sponsor), LUMC/AUMC and Erasmus MC. During this trial there will be two groups: 1. a group of patients with d-TGA, ToF and TA who will undergo a percutaneous intervention for a branch PA stenosis according to standard care (intervention group) and 2. a group of patients with d-TGA, ToF and TA with a similar degree of pulmonary stenosis as group 1 (class IIa indication) who will undergo conservative management for a branch PA stenosis according to standard care (control group). If necessary, the control group will be able to undergo a percutaneous intervention for branch PA stenosis after the examinations at approximately 6 months follow-up, or sooner in case of symptoms. Patients from both groups will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.
Study population: d-TGA post ASO, ToF or TA patients ≥8 years old will be included if they have a class IIa indication for a percutaneous intervention for branch PA stenosis according to the international guidelines. Patients will be excluded if they contraindications for one of the examinations.
Main study parameters/endpoints: the difference in VO2 max (% predicted) as parameter for exercise capacity between the interventional and control group.
- Conditions
- Transposition of Great Vessels, Tetralogy of Fallot, Truncus Arteriosus, Pulmonary Artery Stenosis Supravalvular Congenital, Stent Stenosis, Right Ventricular Dysfunction
- Being tested
- Percutaneous intervention (stent) for PA stenosis
- Keywords
- Exercise capacity
- Medical subject headings
- Transposition of Great Vessels, Tetralogy of Fallot, Truncus Arteriosus, Persistent, Ventricular Dysfunction, Right, Heart Defects, Congenital
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Percutaneous intervention (stent) for PA stenosisProcedure or surgery
Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
| Study group | Role | What they receive |
|---|---|---|
| Interventional group | Experimental | Percutaneous intervention for PA stenosis Receives: Procedure: Percutaneous intervention (stent) for PA stenosis |
| Control group | No intervention | Conservative management (percutaneous intervention for PA stenosis 6 months postponed) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline VO2max as percentage of predicted at 6 months as indication of exercise capacity
using cardiopulmonary exercise test on a treadmill
Measured: change between baseline and 6 months follow-up
Secondary outcomes (18)
Technical success using invasive right ventricular and pulmonary artery pressures and gradients
Technical success of the intervention using invasive right ventricular and pulmonary artery pressures and gradients
Measured: after the intervention, an average of 1 month after baseline
Peak workload (W)
using cardiopulmonary exercise test on a treadmill
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
Peak workload (% predicted)
using cardiopulmonary exercise test on a treadmill
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
O2 pulse (ml)
using cardiopulmonary exercise test on a treadmill
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
O2 pulse (% predicted)
using cardiopulmonary exercise test on a treadmill
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
VE/VCO2 slope
using cardiopulmonary exercise test on a treadmill
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
Right ventricular ejection fraction (%)
using CMR
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
RV strain (%)
using speckle tracking echocardiography and CMR feature tracking
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
RV fractional area change (%)
using echocardiography
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
RV pressure (mmHg)
using echocardiography (TI gradient)
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
RV end-systolic elastance
using pressure-volume analysis
Measured: before and after the intervention, an average of 1 month after baseline
RV end systolic volume (ml and ml/m2)
using CMR
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
RV end diastolic volume (ml and ml/m2)
using CMR
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
RV functional reserve
RVEF dobutamine - RVEF rest using a low dose dobutamine stress MRI
Measured: at baseline and 6 months follow-up in the interventional group from UMC Utrecht and Erasmus MC
RV mass (g and g/m2)
using CMR
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
Right ventricular pulmonary arterial (RV-PA) coupling
using pressure-volume analysis
Measured: before and after the intervention, an average of 1 month after baseline
Lung perfusion (%)
using CMR
Measured: at baseline, 6 months follow-up and 2-4 years follow-up
Quality of Life (QoL) in 4 domains: health and related activities, emotional, social and school/work
using PedsQL questionnaire
Measured: at baseline and 2 weeks follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2023
- Study start18 Apr 2023
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Transposition of Great VesselsStudies of the same condition, open and under way.
- More trials run by UMC UtrechtThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 56 participants (estimated)
Sponsor and investigators
- Lead sponsor
- UMC Utrecht
- Sponsor type
- University, hospital or other
- Collaborators
- Dutch Heart Foundation, Hartekind, Erasmus Medical Center, Leiden University Medical Center, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
- Responsible party
- Principal investigator, Hans Breur, UMC Utrecht
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05809310
- Sponsor's protocol ID
- NL81160
- Status last verified
- Mar 2025
- First submitted
- 15 Mar 2023
- Last updated
- 30 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We will publish the results in peer-reviewed journals and present them at meetings and conferences. As the data is privacy-sensitive, the database will not be publically available. A request for a collaboration can be made via DataverseNL.
Publications
Joosen RS, Voskuil M, Krasemann TB, Blom NA, Krings GJ, Breur JMPJ; Outreach consortium. The effects of percutaneous branch pulmonary artery interventions in biventricular congenital heart disease: study protocol for a randomized controlled Dutch multicenter interventional trial. Trials. 2024 Sep 3;25(1):581. doi: 10.1186/s13063-024-08436-8.
PubMed 39227910
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Branch Pulmonary Artery Stenting in d-TGA, ToF and TA: a Randomized Control Trial
- ClinicalTrials.gov ID
- NCT05809310
- Acronym / sponsor ID
- NL81160
- Conditions
- Transposition of Great Vessels, Tetralogy of Fallot, Truncus Arteriosus, Pulmonary Artery Stenosis Supravalvular Congenital, Stent Stenosis, Right Ventricular Dysfunction
- Keywords
- Exercise capacity
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 56 participants (estimated)
- Lead sponsor
- UMC UtrechtUniversity, hospital or other
- Collaborators
- Dutch Heart Foundation, Hartekind, Erasmus Medical Center, Leiden University Medical Center, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
- Study start
- 18 Apr 2023 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 12 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this randomized controlled trial is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA.
The main question[s] it aims to answer are:
The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.
Participants will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.
Researchers will compare the difference in VO2 max (% predicted) between the interventional group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo a percutaneous intervention for a PA stenosis) and the control group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo conservative management)
Detailed description
Rationale: Postoperative survival of patients with dextro transposition of the great arteries (d-TGA), Tetralogy of Fallot (ToF) and Truncus Arteriosus (TA) has increased over the last decades due to advances in operative techniques and perioperative care. Despite postoperative survival has increased, morbidity of these patients increases during long-term follow-up with a high need for reinterventions. Right ventricular outflow tract (RVOT) obstructions are the most common indication for a reintervention and percutaneous branch pulmonary artery (PA) interventions account for a significant number of these reinterventions. However, the effects of percutaneous branch PA interventions on exercise capacity, RV function and RV adaptation of patients with d-TGA, ToF and TA remains largely unknown. In addition, there is no consensus about the optimal timing for percutaneous interventions for branch PA stenosis in international guidelines.
Objective: The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.
Study design: This is a multicenter randomized controlled trial. Patients will be included from the following Dutch interventional centers for congenital heart disease: UMC Utrecht/WKZ (sponsor), LUMC/AUMC and Erasmus MC. During this trial there will be two groups: 1. a group of patients with d-TGA, ToF and TA who will undergo a percutaneous intervention for a branch PA stenosis according to standard care (intervention group) and 2. a group of patients with d-TGA, ToF and TA with a similar degree of pulmonary stenosis as group 1 (class IIa indication) who will undergo conservative management for a branch PA stenosis according to standard care (control group). If necessary, the control group will be able to undergo a percutaneous intervention for branch PA stenosis after the examinations at approximately 6 months follow-up, or sooner in case of symptoms. Patients from both groups will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.
Study population: d-TGA post ASO, ToF or TA patients ≥8 years old will be included if they have a class IIa indication for a percutaneous intervention for branch PA stenosis according to the international guidelines. Patients will be excluded if they contraindications for one of the examinations.
Main study parameters/endpoints: the difference in VO2 max (% predicted) as parameter for exercise capacity between the interventional and control group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Interventional group | Experimental | Procedure: Percutaneous intervention (stent) for PA stenosisPercutaneous intervention for PA stenosis |
| Control group | No intervention | –Conservative management (percutaneous intervention for PA stenosis 6 months postponed) |
Who may qualify
- Ages
- 8 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Patients with d-TGA post ASO, ToF or TA
- ≥8 years
Key exclusion criteria (14 listed)
- All class IIa indications for a branch PA intervention:
- Persistent decreased RV function (based on gold standard CMR)
- Progressive tricuspid regurgitation (TR) (≥moderate)
- Isolated bifurcation stenosis:
- Unbalanced perfusion (≤35/65%)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Percutaneous intervention (stent) for PA stenosisPercutaneous intervention (stent placement) in one or both of the branch pulmonary arteries | Procedure or surgery | Interventional group |
Primary outcome
Change from baseline VO2max as percentage of predicted at 6 months as indication of exercise capacity
Time frame: change between baseline and 6 months follow-up
using cardiopulmonary exercise test on a treadmill
18 secondary outcomes
Technical success using invasive right ventricular and pulmonary artery pressures and gradients
Time frame: after the intervention, an average of 1 month after baseline
Peak workload (W)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
Peak workload (% predicted)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
O2 pulse (ml)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
O2 pulse (% predicted)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
VE/VCO2 slope
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
Right ventricular ejection fraction (%)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV strain (%)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV fractional area change (%)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV pressure (mmHg)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV end-systolic elastance
Time frame: before and after the intervention, an average of 1 month after baseline
RV end systolic volume (ml and ml/m2)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV end diastolic volume (ml and ml/m2)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
RV functional reserve
Time frame: at baseline and 6 months follow-up in the interventional group from UMC Utrecht and Erasmus MC
RV mass (g and g/m2)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
Right ventricular pulmonary arterial (RV-PA) coupling
Time frame: before and after the intervention, an average of 1 month after baseline
Lung perfusion (%)
Time frame: at baseline, 6 months follow-up and 2-4 years follow-up
Quality of Life (QoL) in 4 domains: health and related activities, emotional, social and school/work
Time frame: at baseline and 2 weeks follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2025.
- Derived from this study: PubMed 39227910Joosen RS, Voskuil M, Krasemann TB, Blom NA, Krings GJ, Breur JMPJ; Outreach consortium. The effects of percutaneous branch pulmonary artery interventions in biventricular congenital heart disease: study protocol for a randomized controlled Dutch multicenter interventional trial. Trials. 2024 Sep 3;25(1):581. doi: 10.1186/s13063-024-08436-8.
- Individual participant dataSharing planned: No. We will publish the results in peer-reviewed journals and present them at meetings and conferences. As the data is privacy-sensitive, the database will not be publically available. A request for a collaboration can be made via DataverseNL.
Related trials for Transposition of Great Vessels
RecruitingPhase 1
Beta-blocker Administration for Cardiomyocyte Division
Tetralogy of Fallot, Double Outlet Right Ventricle
Recruiting
Investigation of Tetralogy of Fallot in Neonates
Tetralogy of Fallot (TOF), Pulmonary Stenosis
RecruitingObservational study
Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease
Congenital Heart Disease, Cyanotic Congenital Heart Disease
Recruiting
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit
RecruitingObservational study
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Adult Congenital Heart Disease, Congenital Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Renée Joosen, MSc contact
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Percutaneous intervention (stent) for PA stenosis in people with Transposition of Great Vessels and Tetralogy of Fallot, run by UMC Utrecht at 4 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hans Breur, MD, PhD (+31 88 75 754 59, h.breur@umcutrecht.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline VO2max as percentage of predicted at 6 months as indication of exercise capacity (time frame: change between baseline and 6 months follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05809310, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2025.